India, Dec. 16 -- Shares of HeartBeam, Inc. (BEAT) slipped over 15% on Monday morning despite the medical technology company announced that FDA has granted 510(k) clearance of the HeartBeam system for comprehensive arrhythmia assessment.
BEAT is currently trading at $2.6326, down $0.4874 or 15.62%, on the Nasdaq. The stock opened its trading at $3.4700 after closing Friday at $3.1200. The stock has traded between $2.2800 and $3.4700 in the past 52-week period.
HeartBeam announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance of the HeartBeam system for comprehensive arrhythmia assessment.
With its patented design, the HeartBeam device is the first-of-its-kind to receive FDA clearance. As a high-fidelity elec...